<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03182088</url>
  </required_header>
  <id_info>
    <org_study_id>N-49-2017</org_study_id>
    <nct_id>NCT03182088</nct_id>
  </id_info>
  <brief_title>Norepinephrine Infusion Different Doses in Cesarean Delivery</brief_title>
  <official_title>Norepinephrine Infusion for Prevention of Post-spinal Hypotension During Cesarean Delivery: A Randomized Controlled Dose Finding Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      three doses (0.05 mcg/Kg/min, 0.1 mcg/Kg/min, and 0.15 mcg/Kg/min) of norepinephrine will be
      compared for prophylaxis against Post-spinal anesthesia hypotension during Cesarean delivery.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Maternal hypotension is a common complication after spinal anesthesia for cesarean delivery
      (CD). Using vasopressors have been considered a gold standard for prevention of post-spinal
      hypotension (PSH) during CD.

      Norepinephrine (NE) is a potent vasopressor characterized by both α adrenergic agonist
      activity in addition to a weak β adrenergic agonist activity; thus, NE is considered a
      vasopressor with minimal cardiac depressant effect; these pharmacological properties would
      make NE an attractive alternative to phenylephrine and ephedrine (the most commonly used
      vasopressors in obstetric anesthesia).

      Norepinephrine has been recently introduced as a prophylactic vasopressor during CD with
      promising results; However, the optimum dose for efficient prophylaxis with the least side
      effects is not known.

      In this study, three doses (0.05, 0.1, 0.15 mcg/Kg/min) of norepinephrine will be compared
      for prophylaxis against PSH during CD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 15, 2017</start_date>
  <completion_date type="Actual">December 30, 2017</completion_date>
  <primary_completion_date type="Actual">December 25, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>postspinal hypotension</measure>
    <time_frame>30 minutes after spinal anesthesia</time_frame>
    <description>The number of patients who develop hypotension (defined as decreased SBP less than 80% of the baseline reading during the period from intrathecal injection till delivery of the fetus) after spinal block divided by the total number in the group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>severe postspinal hypotension</measure>
    <time_frame>30 minutes after spinal anesthesia</time_frame>
    <description>The number of patients who develop hypotension (defined as decreased SBP less than 60% of the baseline reading during the period from intrathecal injection till delivery of the fetus) after spinal block divided by the total number in the group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-delivery hypotension</measure>
    <time_frame>10 minutes after delivery</time_frame>
    <description>number of patients who develop hypotension (defined as decreased SBP less than 80% of the baseline reading after delivery of the fetus and starting oxytocin infusion)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>systolic blood pressure</measure>
    <time_frame>60 minutes after spinal block</time_frame>
    <description>systolic blood pressure measured in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>diastolic blood pressure</measure>
    <time_frame>60 minutes after spinal block</time_frame>
    <description>diastolic blood pressure measured in mmHg</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>heart rate</measure>
    <time_frame>60 minutes after spinal block</time_frame>
    <description>heart rate measured in beats per minute</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>intraoperative hypertension</measure>
    <time_frame>60 minutes after spinal block</time_frame>
    <description>number of patients who develop intraoperive hypertension (defined as increased systolic blood pressure by more than 20% of the baseline reading) divided by the total number of patients in the group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>incidence of nausea and vomiting</measure>
    <time_frame>60 minutes after spinal block</time_frame>
    <description>number of patients who develop nausea and vomiting divided by the total number of patients in the group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ephedrine consumption</measure>
    <time_frame>60 minutes after spinal block</time_frame>
    <description>total amount of ephedrine consumed during the operation (measured in milligrams)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atropine consumption</measure>
    <time_frame>60 minutes after spinal block</time_frame>
    <description>total amount of atropine consumed during the operation (measured in milligrams)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>APGAR score</measure>
    <time_frame>1 minute after delivery</time_frame>
    <description>APGAR score for detection of the well being of the fetus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>APGAR score</measure>
    <time_frame>10 minutes after delivery</time_frame>
    <description>APGAR score for detection of the well being of the fetus</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">288</enrollment>
  <condition>Cesarean Section Complications</condition>
  <arm_group>
    <arm_group_label>0.05 mcg /Kg/min group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients will receive spinal anesthesia through 10 mg Bupivacaine, then start norepinephrine infusion (0.05 mcg/Kg/min)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.1 mcg/Kg/min group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients will receive spinal anesthesia through 10 mg Bupivacaine, then start 'norepinephrine infusion (0.1 mcg/Kg/min)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.15 mcg/Kg/min group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients will receive spinal anesthesia through 10 mg Bupivacaine, then start 'norepinephrine infusion (0.15 mcg/Kg/min)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>norepinephrine infusion (0.05 mcg/Kg/min)</intervention_name>
    <description>The patients will receive a bolus of 10 mcg norepinephrine followed by norepinephrine infusion of (0.05 mcg/Kg/min)</description>
    <arm_group_label>0.05 mcg /Kg/min group</arm_group_label>
    <other_name>noradrenaline infusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>norepinephrine infusion (0.1 mcg/Kg/min)</intervention_name>
    <description>The patients will receive a bolus of 10 mcg norepinephrine followed by norepinephrine infusion of (0.1 mcg/Kg/min)</description>
    <arm_group_label>0.1 mcg/Kg/min group</arm_group_label>
    <other_name>noradrenaline infusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>norepinephrine infusion (0.15 mcg/Kg/min)</intervention_name>
    <description>The patients will receive a bolus of 10 mcg norepinephrine followed by norepinephrine infusion of (0.15 mcg/Kg/min)</description>
    <arm_group_label>0.15 mcg/Kg/min group</arm_group_label>
    <other_name>noradrenaline infusion</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bupivacaine</intervention_name>
    <description>The patient will receive spinal anesthesia using Bupivacaine (10 mg).</description>
    <arm_group_label>0.05 mcg /Kg/min group</arm_group_label>
    <arm_group_label>0.1 mcg/Kg/min group</arm_group_label>
    <arm_group_label>0.15 mcg/Kg/min group</arm_group_label>
    <other_name>spinal anesthesia</other_name>
    <other_name>Heavy marcaine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  full term

          -  singleton

          -  pregnant women

          -  scheduled for elective cesarean delivery

        Exclusion Criteria:

          -  cardiac morbidities

          -  hypertensive disorders of pregnancy

          -  peripartum bleeding

          -  baseline systolic blood pressure (SBP) &lt; 100 mmHg

          -  body mass index &gt; 35 will be excluded from the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmed Mukhtar, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Head of research committee section in anesthesia department</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cairo University</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 7, 2017</study_first_submitted>
  <study_first_submitted_qc>June 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2017</study_first_posted>
  <last_update_submitted>April 15, 2018</last_update_submitted>
  <last_update_submitted_qc>April 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Ahmed Hasanin</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Bupivacaine</mesh_term>
    <mesh_term>Norepinephrine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

